Competitor Landscape: Spondyloarthritis

2018-11-30
Price :
Published : Nov-2018
No. of Pages : 64

Competitor Landscape: Spondyloarthritis

Summary

Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the spondyloarthritis (SpA) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher –
– Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
– Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
– Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
– Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019

Key Highlights

– Given that only 187 patients are currently enrolled in upadacitinib’s Phase II/III SELECT-Axis 1 trial in AS, it is assumed that AbbVie will need to run a Phase III program before filing
– Secukinumab’s EU label update for PsA will bring it in-line with its US label, and is expected to become a key point of differentiation
– Change in primary completion date of the Phase III COAST-X trial is not expected to influence ixekizumab’s regulatory timeline in any way, with Lilly stating that it expects to file for regulatory approval of ixekizumab in AS and nr-axSpA, simultaneously, by YE 2018.

Scope

– The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
– Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix
– Forecasts are presented in pipeline forecast figures & detailed tables
– ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to buy

– Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
– Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
– Reviews ongoing lifecycle management strategies for existing players in the market
– A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products Summary An allergy or allergic disease is a condition that arises from an adverse reaction to an exogenous antigen, a substance that invokes an immunological response. These conditions are extremely common. The number of people diagnosed with allergic diseases is rising rapidly on a global scale, which is attributable to factors such as population growth and increased urbanization and pollution. In addition, for a minority of these patients, allergic reactions can be severe, debilitating, or even life-threatening. Despite this high disease burden, treatment options are limited for many conditions and patients often recei......
$6995

Digital Therapeutics and Their Impact on Healthcare

Digital Therapeutics and Their Impact on Healthcare Summary Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx) represent a new way of treatment in which digital systems are used as regulatory?approved, to treat medical conditions as prescribed therapeutic interventions. There is a growing number of DTx developed on the market today as well as pipeline products in development following internationally-recognized, quality, design and manufacturing standards. DTx will provide a new approach to treatment and disease management in which patients have the possibility to learn more about their conditions and treatment options and this will lead to manage their own health and disease conditions. This report provides an overview of cur......
$7995

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends – Q1 2019

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019 Summary GlobalData's "Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information o......
$1500

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Italy

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Italy. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Italy. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2018. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on th......
$3500

Diabetic Nephropathy Global Clinical Trials Review, H1, 2019

Diabetic Nephropathy Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Diabetic Nephropathy Global Clinical Trials Review, H1, 2019" provides an overview of Diabetic Nephropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500

Dysthymia Global Clinical Trials Review, H1, 2019

Dysthymia Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dysthymia Global Clinical Trials Review, H1, 2019" provides an overview of Dysthymia clinical trials scenario. This report provides top line data relating to the clinical trials on Dysthymia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500

Diverticulitis Global Clinical Trials Review, H1, 2019

Diverticulitis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Diverticulitis Global Clinical Trials Review, H1, 2019" provides an overview of Diverticulitis clinical trials scenario. This report provides top line data relating to the clinical trials on Diverticulitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500

Endometrial Cancer Global Clinical Trials Review, H1, 2019

Endometrial Cancer Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Endometrial Cancer Global Clinical Trials Review, H1, 2019" provides an overview of Endometrial Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Endometrial Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trial......
$2500

Dermatomycoses Global Clinical Trials Review, H1, 2019

Dermatomycoses Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dermatomycoses Global Clinical Trials Review, H1, 2019" provides an overview of Dermatomycoses clinical trials scenario. This report provides top line data relating to the clinical trials on Dermatomycoses. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy